The lability of the mononuclear octahedral complex tris(5-methyl-2-(1‘-methylbenzimidazol-2-yl)-pyridine)cobalt(II), [Co( 2 ) 3 ] 2+, is compared with the dinuclear triple-helical complex tris[bis[1-methyl-2-(5‘-methylpyrid-2‘-yl]benzimidazol-5-yl]methane]dicobalt(II), [Co 2 ( 1a ) 3 ] 4+ . [Co( 2 ) 3 ] 2+ undergoes rapid isomerization between mer and fac forms ( k 298 ( mer − fac ) = 1.6 ± 0.2 s - 1 ) in acetonitrile while the racemization of (−) 589 -[Co 2 ( 1a ) 3 ] 4+ is roughly 10 5 times slower ( k 298 = 1.4 ± 2 10 - 5 s - 1 ). The pressure dependence of the isomerization of [Co( 2 ) 3 ] 2+ suggests a dissociatively activated process. The racemization of (−) 589 -[Co 2 ( 1a ) 3 ] 4+ is found to be independent of pH above pH 4, and is not affected by added cobalt(II) or a change of solvent. Ligand exchange between [Co 2 ( 1b ) 3 ] 4+ ( 1b = bis[1-ethyl-2-(5‘-methylpyrid-2‘-yl)benzimidazol-5-yl]methane) and free 1a may be followed by electrospray mass spectrocopy and establishes the mechanism of formation of the triple helix to be initial formation of mononuclear [Co( 1a ) 3 ] 2+ followed by capping by a second cobalt to give [Co 2 ( 1a ) 3 ] 4+ . The slow racemization of (−) 589 -[Co 2 ( 1a ) 3 ] 4+ is attributed to the very slow dissociation of a cobalt ion from the triple helix. This inertness is attributed to the rigidity of the ligand and the tight pitch of the helix.
No takes yet. Share an insight, caveat, or question.
Charbonnière et al. (1997) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: